Purpose: To identify the potential of semi-quantitative enhancement-analysis in breast MRI to predict disease-related death in primary breast cancer patients.

Materials And Methods: The present study was planned and conducted according to international recommendations. All patients referred for pretherapeutic staging of primary breast cancer during 24 consecutive months were included into the study collective. They were followed-up by our multidisciplinary breast center. For semi-quantitative MRI-analysis dedicated CAD-software (computer assisted diagnosis) was used. Association between enhancement parameters and disease-related survival was investigated using Cox proportional-hazards -regression (CR).

Results: A total of 115 patients were eligible for CR analysis. Median follow-up time was 52 months. In 15 patients, disease-related death occurred. CR analysis identified four enhancement parameters as independent and significant (P < 0.001) predictors of the endpoint. Coefficients were "Initial enhancement" (B = 0.0166), "Time to peak-enhancement" (B = 1.0573), "Tumor volume" (B = 0.0175), and proportion of "tumor volume" showing "slow initial enhancement" followed by a "persistent" curve-type (B = -0.0586).

Conclusion: This study demonstrates the significant relationship between semi-quantitative enhancement analysis in breast MRI and disease-related death of breast cancer patients. As results were extracted from a routine staging examination, MRI noninvasively provides not only diagnostic information but also outcome data at one step. Future studies should address the impact of these findings on patient management and therapeutic approach.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.23812DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
disease-related death
12
breast mri
8
primary breast
8
enhancement parameters
8
"tumor volume"
8
breast
7
patients
5
association survival
4
survival patients
4

Similar Publications

The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey.

BMC Cancer

January 2025

Young Academy of Gynecologic Oncology (JAGO), Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), Berlin, Germany.

Background: The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecologic oncology are very limited. The aim of this survey was to provide a real-world overview of the experiences and the current state of irAE management of ICIs in Germany, Switzerland, and Austria.

View Article and Find Full Text PDF

Background: Over the past twenty years, the post-cancer rehabilitation has been developed, usually in a hospital setting. Although this allows better care organization and improved security, it is perceived as stressful and restrictive by the "cancer survivor". Therefore, the transfer of benefits to everyday life is more difficult, or even uncertain.

View Article and Find Full Text PDF

Triaging mammography with artificial intelligence: an implementation study.

Breast Cancer Res Treat

January 2025

Google Health, 1600 Amphitheatre Pkwy, Mountain View, CA, 94043, USA.

Purpose: Many breast centers are unable to provide immediate results at the time of screening mammography which results in delayed patient care. Implementing artificial intelligence (AI) could identify patients who may have breast cancer and accelerate the time to diagnostic imaging and biopsy diagnosis.

Methods: In this prospective randomized, unblinded, controlled implementation study we enrolled 1000 screening participants between March 2021 and May 2022.

View Article and Find Full Text PDF

Background: The identification of circulating potential biomarkers may help earlier diagnosis of breast cancer, which is critical for effective treatment and better disease outcomes. We aimed to study the role of circ-FAF1 as a diagnostic biomarker in female breast cancer using peripheral blood samples of these patients, and to investigate the relation between circ-FAF1 and different clinicopathological features of the included patients.

Methods And Results: This case-control study enrolled 60 female breast cancer patients and 60 age-matched healthy control subjects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!